Ibex Technologies Stock

IBT

CA4489375085

OTC Markets Traded

on all subscriptions*

Last days

Enjoy this offer

* See conditions under "Our services"

Latest news : Ibex Technologies

04/08/24	IBEX Technologies Inc.'s Equity Buyback announced on July 17, 2023, has expired.	CI
08/04/24	IBEX Completes C$37.9-Million Sale Of the Company	MT
08/04/24	BBI Solutions OEM Limited completed the acquisition of IBEX Technologies Inc. from Milfam LLC, McLean Capital Inc., Paul Baehr and others.	CI
03/04/24	IBEX Shareholders Approve the C$37.9-Million Sale of Company	MT
26/03/24	Refile: IBEX Reports Results For The Second Quarter And Six Months Ending Jan. 31, 2024	MT
25/03/24	IBEX Reports Results For The Second Quarter And Six Months Ending Jan. 31, 2024	MT
22/03/24	IBEX Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	CI
22/03/24	Tranche Update on IBEX Technologies Inc.'s Equity Buyback Plan announced on July 17, 2023.	CI
22/03/24	IBEX Reports Results For The Second Quarter And Six Months Ending January 31, 2024	MT
23/02/24	IBEX Technologies Issues Management Circular Ahead of Vote of C$37.9-Million Acquisition Offer	MT
12/02/24	IBEX Technologies Signs Definitive Agreement to Sell Company for $1.45 Cash Per Share	MT
12/02/24	15720273 Canada Inc. entered into a binding acquisition agreement to acquire IBEX Technologies Inc. from Milfam LLC, McLean Capital Inc., Paul Baehr and others for CAD 35.5 million.	CI
14/12/23	Tranche Update on IBEX Technologies Inc.'s Equity Buyback Plan announced on August 2, 2022.	CI

More news

Press Releases: Ibex Technologies

09/04/24	IBEX Technologies : BBI Solutions Announces Successful Closing of Acquisition of IBEX Technologies	PU
08/04/24	IBEX Completes Sale of the Company	GL
08/04/24	Canadian Investment Regulatory Organization Trading Halt - IBT	AQ
03/04/24	IBEX Shareholders Approve Sale of the Company	GL
22/03/24	IBEX Reports Results for the Second Quarter and Six Months Ended January 31, 2024	GL

More press releases

News in other languages: Ibex Technologies

12/02/24

TECHNOLOGIES IBEX SIGNE UNE ENTENTE DÉFINITIVE VISANT LA VENTE DE LA SOCIÉTÉ POUR UNE CONTREPARTIE AU COMPTANT DE 1,45 $ PAR ACTION

More news

Managers and Directors: Ibex Technologies

Manager	Title	Age	Since
Belinda Franco DFI	Director of Finance/CFO	-	06/11/2020
Mahendra Pallapothu COO	Chief Operating Officer	-	17/09/2018

Director	Title	Age	Since
Robert de Luccia BRD	Director/Board Member	80	01/01/2000
Danilo Netto BRD	Director/Board Member	-	01/01/2007
Bruce P. Connop BRD	Director/Board Member	57	11/10/2017

More insiders

IBEX Technologies Inc., through its wholly owned subsidiary, IBEX Pharmaceuticals Inc., manufactures and markets enzymes for biomedical use. IBEX Pharmaceutical Inc.â€™s primary business is the manufacture and selling of high purity enzymes for in-vitro diagnostics and research. The Company also makes and sell osteoarthritis kits (ELISAâ€™s) for pre-clinical research. The Company has developed a proprietary expression for the production of its enzymes in Flavobacterium heparinum. This expression system allows for producing each glycosaminoglycan (GAG) enzyme separately from other enzymes therefore achieving the highest purity using a well-defined proprietary purification scheme. The Company operates in one industry segment: the production and sale of diagnostic products.

Employees

Sector

More about the company